

Vanguard CPV, ενέσιμο διάλυμα για σκύλους

Authorised

- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:

Vanguard CPV, ενέσιμο διάλυμα για σκύλους

Active substance:

Canine parvovirus, strain NL-35-D, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, strain NL-35-D, Live

7.00 log₁₀ unit(s) / 1.00 50% tissue culture infectious dose/dose

Pharmaceutical form:

Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI05

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Cyprus

Available in:

Cyprus

Package description:

Available only in Greek

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Hellas S.A.

Marketing authorisation date:

15/11/1995

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Veterinary Services, Ministry Of Agriculture, Natural Resources And Environment

Authorisation number:

16339

Date of authorisation status change:

15/06/2005

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.